DUBLIN--(BUSINESS WIRE)--The "Fabry Disease - Market Insights, Epidemiology and Market Forecast - 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.
The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Anderson-Fabry Disease from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Anderson-Fabry Disease till 2025. It also covers market drivers, market barriers and unmet medical need.
Our report provides the subtype specific prevalent population i.e. Classic Fabry Disease and Later-onset Fabry disease. According to research, the prevalent population of Anderson-Fabry Disease is expected to reach up to XXX cases by the end of 2025 at a CAGR of 1.3% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.
Fabry Disease market has experienced a continuous growth due to approved therapies such as Fabrazyme (agalsidase beta) from Sanofi Genzyme and Replagal (ERT based therapy) from Shire. Sanofi Genzyme is currently dominating the Fabry market with its lead product Fabrazyme.
United States contributes the major share of Fabry disease market as compared to EU5 countries and Japan.
Key Topics Covered:
1. Report Introduction
2. Disease Background and Overview
3. Introduction
4. Epidemiology and Patient Population
5. Treatment Practices
6. Treatment Goals
7. Treatment Algorithm
8. Marketed Drugs List
9. Marketed Drugs
Companies Mentioned
- Amicus Therapeutics, Inc.
- Shire Plc.
- Sanofi-Aventis
- Protalix Biotherapeutics
